Ibrutinib/Venetoclax Produces Encouraging Results in Relapsed/ Refractory CLL

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [1] Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study
    Munir, Talha
    Rawstron, Andrew
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca
    Bishop, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John
    Patten, Piers
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher
    Forconi, Francesco
    Hillmen, Peter
    LEUKEMIA & LYMPHOMA, 2020, 61 : 227 - 228
  • [2] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: The CLARITY Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 20 - 21
  • [3] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
    Hillmen, Peter
    Rawstron, Andy
    Brock, Kristian
    Vicente, Samuel Munoz
    Yates, Francesca
    Bishop, Rebecca
    Macdonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    BLOOD, 2018, 132
  • [4] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
    Munir, T.
    Rawstron, A.
    Brock, K.
    Vicente, S. Munoz
    Yates, F.
    Bishop, R.
    Macdonald, D.
    Fegan, C.
    McCaig, A.
    Schuh, A.
    Pettitt, A.
    Gribben, J. G.
    Patten, P. E.
    Devereux, S.
    Bloor, A.
    Fox, C. P.
    Forconi, F.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 25 - 25
  • [5] Durability of Response to Venetoclax (VEN) in Patients with CLL Relapsed/Refractory to Ibrutinib and/or Idelalisib
    Byrd, J.
    Wierda, W.
    Davids, M.
    Choi, M.
    Furman, R.
    Mato, A.
    Zhou, L.
    Verdugo, M.
    Potluri, J.
    Coutre, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 83 - 84
  • [6] Durability of response to venetoclax (VEN) in patients with CLL relapsed/refractory to ibrutinib and/or idelalisib.
    Byrd, John C.
    Wierda, William G.
    Davids, Matthew Steven
    Choi, Michael Y.
    Furman, Richard R.
    Mato, Anthony R.
    Zhou, Lang
    Verdugo, Maria E.
    Potluri, Jalaja
    Coutre, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] VENETOCLAX IS ACTIVE IN CLL PATIENTS WHO HAVE RELAPSED AFTER OR ARE REFRACTORY TO IBRUTINIB OR IDELALISIB
    Coutre, S.
    Wierda, W.
    Choi, M.
    Davids, M. S.
    Cheson, B. D.
    Furman, R. R.
    Lamanna, N.
    Barr, P. M.
    Eradat, H.
    Halwani, A.
    Heffner, L.
    Chyla, B.
    Zhu, M.
    Potluri, J.
    Verdugo, M.
    Humerickhouse, R.
    Mato, A. R.
    Jones, J.
    HAEMATOLOGICA, 2016, 101 : 231 - 232
  • [8] Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
    Ujjani, Chaitra S.
    Lai, Catherine
    Leslie, Lori A.
    Ramzi, Pari
    Tan, Ming
    Wang, Siyu
    Wang, Hongkun
    Shim, Eunice
    Swanson, Nicole
    Broome, Catherine M.
    Gopal, Ajay K.
    Smith, Stephen D.
    Warren, Edus H.
    Blue, Katie
    Kdiry, Sabrina
    Till, Brian G.
    Lynch, Ryan C.
    Shadman, Mazyar
    Johnson, Michael
    Coye, Hilary
    Shelby, Megan
    Tseng, Yolanda D.
    Shustov, Andrei
    Maloney, David G.
    Cheson, Bruce D.
    BLOOD, 2020, 136
  • [9] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [10] Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.
    Jones, Jeffrey Alan
    Wierda, William G.
    Choi, Michael Y.
    Davids, Matthew Steven
    Cheson, Bruce D.
    Furman, Richard R.
    Lamanna, Nicole
    Barr, Paul M.
    Eradat, Herbert Aaron
    Halwani, Ahmad Sami
    Heffner, Leonard T.
    Chyla, Brenda
    Zhu, Ming
    Potluri, Jalaja
    Verdugo, Maria E.
    Humerickhouse, Rod
    Mato, Anthony R.
    Coutre, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345